Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Severe osteoporosis in tr… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Severe osteoporosis in transwomen due to cessation of estrogen replacement after gender-confirming surgery

Konferensbidrag (offentliggjort, men ej förlagsutgivet)
Författare Ralph Decker
Jens Jacobeit
Publicerad i 25th WPATH Symposium in Buenos Aires, Argentina
Publiceringsår 2018
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för pediatrik
Språk en
Länkar wpath2018.shdlr.com/conferences/tal...
Ämnesord Gender dysphoria, cross-sex hormonal treatment, gender-confirming surgery (GCS), Estradiol replacement
Ämneskategorier Endokrinologi

Sammanfattning

Background The effect of sex steroids on the bone health of transgender individuals has been scarcely studied (1). In some male-to-female transgender, there was a lack of Estradiol treatment after gender-confirming surgery (GCS) in the 1980th and 1990th in a subgroup of patients. Lack of Estradiol is known to decrease bone mineral density (BMD) and increase the risk of fracture, especially in postmenopausal women (2). Objective & hypothesis Cessation of cross-sex hormonal treatment after GCS leads to osteoporosis. Material/ Methods A We studied prospectively a cohort of 288 transgender individuals male-to-female between 2009 - 2017. In 37 (12.8%) out of 288 patients, Dual-Energy-X-ray Absorptiometry (DXA) was performed using a DXA Luna Prodigy when hypogonadism was present (3). BMD references were used according to the original biological sex. Results In 28 cases out of 37 (76%) in whom DXA was performed, either osteopenia (BMD -1.0 to -2.5) or osteoporosis (BMD < -2.5) was detected 15.5 years after GCS without or insufficient Estradiol treatment postoperatively. Low BMD was correlated to low estradiol values before estradiol treatment was reintroduced. While lumbar osteopenia was improved after 2.3 years, osteoporosis could only be slightly enhanced, but none of the cases was fully reverted. Additionally, a significant number (23/37; 62%) of patients dropped out of further follow-up and compliance to take the Estradiol medication was moderate in the remaining. Discussion Lack of sufficient Estradiol treatment after successful gender-confirming surgery in male-to-female transgender causes osteopenia in up to 49% of these trans-women and osteoporosis in up to 38%. Both lumbar as well as femoral BMD were markedly decreased. Nevertheless, a fracture was detected solely in one case. The relationship between bone density and fracture risk, however, is a continuum, without a clear “fracture threshold” (3). The fracture risk in the future remains high in these mean 45 year old patients, ranging from 21 to 78 years. References 1. Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C, Nippoldt TB, Prokop LJ, Murad MH (2017) Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab, 102(11):3904–3913 2. Black DM, Rosen CJ (2016) Postmenopausal osteoporosis. N Engl J Med 374(3):254–262 3. Camacho PM et al (2016) American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2016 Sep 2;22(Suppl 4)

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?